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Abstract 
Main problem 
Increasing evidence indicates a role of vitamin D in the immune system affecting response to 
infections. We aimed to characterize the role of vitamin D status, i.e. deficiency (25-OH 
vitamin D [25-OHD] < 50nmol/l) and no deficiency (25-OHD ≥ 50nmol/l) in incident 
infections after liver transplantation. 
 
Methods 
In 135 liver transplant recipients blood samples drawn at time of liver transplantation and 6 
months afterwards were used to determine 25-OHD levels. Incident infections episodes were 
prospectively collected within the STCS database. Poisson regression was applied to address 
associations between vitamin D status and incident infections. 
 
Results 
Vitamin D deficiency was common at time of transplantation and 6 months afterwards 
without a significant change in median 25-OHD levels. In univariable analyses vitamin D 
deficiency was a risk factor for incident infections in the first 6 months post-transplant (IRR 
1.52, 95% CI 1.08-2.15, P=0.018) and for bacterial infections occurring after 6 up to 30 
months post-transplant (IRR 2.29, 95% CI 1.06-4.94, P=0.034). These associations were not 
detectable in multivariable analysis with adjustment for multiple confounders. 
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Conclusions 
Efforts to optimize vitamin D supplementation in liver transplant recipients are needed. Our 
data question the role of vitamin D deficiency in incident infections. 
 
(ClinicalTrials.gov number: NCT01204944) 
Introduction 
Vitamin D deficiency is highly prevalent in patients with end-stage organ failure including 
patients listed for organ transplantation [1-3]. The majority of vitamin D is synthesized in the 
skin via ultraviolet light exposure, only a small proportion is ingested by food intake. 25-
position hydroxylation of vitamin D takes place in the liver forming 25-OH vitamin D (25-
OHD) which is used as an indicator of vitamin D status [4]. In the kidneys an additional 1-
position hydroxylation is performed resulting in the biologically active form 1, 25-(OH)2 
vitamin D [4].  
 
Besides its well-established role for bone metabolism, vitamin D has been linked to infections 
[5], cardiovascular diseases and overall survival [6, 7] in the general population. In chronic 
liver disease vitamin D deficiency has been associated with the degree of liver dysfunction 
[8], infections [9] and even mortality [8, 9]. Some data suggest an influence of vitamin D on 
infections in solid organ transplant recipients [10, 11]. Beyond assessment of the vitamin D 
status at time of transplantation and 6 months after transplantation, our study specifically 
addressed the question whether vitamin D deficiency is associated with incident infections in 
liver graft recipients. We divided a total observation period of 2.5 years into two periods, the 
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first 6 months after transplantation and 6 months post-transplant until 2.5 years post-
transplant. Our analysis took the vitamin D status at time of transplantation and at 6 months 
post-transplant for the first period and the second period into account, respectively.  
 
Patients and methods 
Study design, population and patient-related data 
This study was performed within the Swiss Transplant Cohort Study (STCS, www.stcs.ch, 
ClinicalTrials.gov number: NCT01204944). The STCS prospectively collects data and 
biosamples from all 6 transplant centers in Switzerland (i.e. Basel, Bern, Geneva, St. Gallen, 
Lausanne and Zurich). Since May 2008 all solid organ transplants have been registered 
within the STCS database, for data analysis and sampling an informed consent is obtained. 
Enrollment is > 93% of all transplantations in Switzerland [12]. The STCS was approved by 
the Ethic Committees of all participating institutions. Liver transplantations of enrolled 
participants were performed between May 2008 and July 2011. Enrolment included liver 
transplant recipients within the STCS, available plasma samples and ongoing informed 
consent at the follow up of 2.5 years after transplantation. With the exception of information 
about vitamin D supplementation, which was retrospectively added by patient chart review, 
all other data were prospectively collected. Dedicated professionals supervised by transplant 
infectious diseases physicians prospectively record infections every 6 months in the first year 
post-transplant and afterwards every year. For analysis of the association between vitamin D 
levels and infections, only clinical relevant infections, i.e. symptomatic and, if possible, 
resulting in targeted treatment, were considered. Clinical presentations interpreted suggestive 
of an infectious etiology and prompting initiation of antimicrobial treatment by the treating 
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physicians were rated as probable infections, if routine diagnostics remained without 
identification of a pathogen. For the subgroup analysis of bacterial infections, we defined 
proven bacterial infections as clinically apparent infections combined with detection of the 
causative bacterium and initiation of targeted antimicrobial treatment.  
 
Laboratory analysis 
For laboratory analyses, prospectively collected blood samples of the participating transplant 
recipients were retrieved from the STCS biobank. Blood samples drawn at the time of 
transplant and samples obtained 6 months post-transplant were used for centralized, uniform 
measurement at the Institute of Clinical Chemistry of the University Hospital Zurich. 25-OH 
vitamin D measurement was performed with Roche Diagnostics Vitamin D total assay on 
Cobas
®
 8000 (Roche Diagnostics, Mannheim, Germany). 
 
Vitamin D status was categorized as deficiency, if 25-OH vitamin D < 50nmol/l (20ng/ml), 
whereas 25-OH vitamin D levels ≥ 50nmol/l were considered as no deficiency. 
 
Statistical analysis 
All statistical analyses were performed with R (version 3.3.2). Continuous variables were 
reported as median and interquartile range (IQR), categorical variables as absolute numbers 
and frequencies (%). Statistical testing was performed with two-sided tests, P-values < 0.05 
were considered significant. Wilcoxon rank-sum test was used for comparison of continuous 
variables between two groups, whereas Wilcoxon matched-pairs signed-rank test was applied 
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for pairwise comparisons. Multiple group comparison was performed with Kruskal-Wallis 
test. Linear relationships were assessed by Pearson correlation. Categorical variables were 
compared using Fisher’s Exact test. For investigation of the association between vitamin D 
levels and incident infections, we defined two observation periods. The first period referred 
to the timespan from transplantation to 6 months post-transplant, for this analysis vitamin D 
values measured at time of transplantation were considered. The second period comprised the 
timespan beginning after 6 months post-transplant until 30 months post-transplant, for this 
period, 25-OH vitamin D values determined at 6 months after transplantation were taken into 
account. For analysis regarding defined time periods, patients with shorter follow up either 
due to death or lost to follow up were excluded (5 out of 135 liver recipients for an 
observation period up to 30 months). Poisson regression was applied to identify risk factors 
associated with infections. In the univariable analysis we tested the variables age, sex, type of 
graft (whole vs. split), vitamin D status (no deficiency vs. deficiency), use of induction 
immunosuppression, body mass index (BMI) and self-reported mobility. In addition, model 
of end stage liver disease (MELD) and Child-Pugh score were added exclusively for the 
analysis on vitamin D levels peri-transplant and incident infections within the first 6 months 
after transplantation, as prior research highlighted relevance of these parameters in cirrhotic 
patients as well as in the early post-transplant period [13, 14]. If number of events was 
sufficient, all these variables were taken into the multivariable model with the exception of 
variables showing co-linearity. For the analysis of the association between vitamin D levels 
and incident proven bacterial infections after 6 up to 30 months after transplantation, we 
decided to limit our multivariable analysis on 5 independent variables with respect to the 
number of events (n=49) to avoid over-adjustment. The present model was chosen under 
consideration of best fit and the prerequisite of inclusion of vitamin D levels. Vitamin D 
supplementation at time transplant and 6 months after transplantation were intentionally not 
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considered in analysis, as we addressed the associations with vitamin D levels itself and not 
the presence of supplementation therapy.  
 
Results 
Patients’ characteristics 
Of the 135 participants 64.4% were males, 132 (97.8%) were Caucasian. Median age of liver 
recipients was 54 years (IQR 45-61). The most common reasons for liver transplantation 
were hepatitis C (n=30, 22.2%), alcohol abuse (n=28, 20.7%), hepatitis B (n=15, 11.1%) or 
incidence of hepatocellular carcinoma (n=22, 16.3%). 126 (93.3%) grafts derived from 
deceased donors, 6 (4.4%) from living related donors and 3 (2.2%) from a living unrelated 
donor. At time of transplantation median model of end stage liver disease (MELD) score was 
20 (IQR 14-28). Induction immunosuppression was administered in 90 (66.7%) participants. 
Peri-transplant 24 (17.8%) participants received cholecalciferol (median dose 800IU) and 2 
(1.5%) participants 1, 25-dihydroxycholecalciferol (median dose 0.25µg). Six months post-
transplant 55 (40.7%) liver recipients obtained supplementation with cholecalciferol (median 
dose 800IU) and 2 (1.5%) participants with 1, 25-dihydroxycholecalciferol (median dose 
0.125 µg). 
 
Vitamin D status 
Peri-transplant the majority of liver transplant recipients showed a deficiency of 25-OHD 
(n=96, 71.1%). In 39 (28.9%) individuals 25-OHD levels of at least 50nmol/l were detected. 
Six months post-transplant 88 (66.2%) patients had vitamin D deficiency. No vitamin D 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
deficiency was present in 45 (33.8%) individuals (Figure 1). 25-OHD measured peri-
transplant (median 32.5nmol/l, IQR 12.6-55.8nmol/l) and 6 months post-transplant (median 
35.4nmol/l, IQR 19.7-62.7nmol/l) did not significantly differ (P=0.067). At transplantation 
88.0% of liver recipients without vitamin D supplementation showed 25-OHD values < 
50nmol/l (vs. 50.0% of recipients treated with vitamin D analogues). Six months after 
transplantation 50.0% of liver recipients with supplementation therapy and 77.5% without 
supplementation were vitamin D deficient (25-OHD < 50nmol/l). 
 
Vitamin D status and infections 
Infections within the first 6 months post-transplant of liver recipients 
Overall 190 infections affecting 94 participants occurred within the first 6 months after liver 
transplantation: 98 (51.6%) bacterial, 41 (21.6%) viral, 6 (3.2%) fungal infections, 1 (0.5%) 
parasitic infection and 44 (23.2%) suspected infections prompting antimicrobial treatment, in 
which identification of the causative pathogen was not successful (Figure 2). The most 
common, by bacterial infections affected sites were the gastrointestinal tract (n=40, 40.8%), 
bacteremia (n=22, 22.5%), urinary tract (n=13, 13.3%) and respiratory tract (n=5, 5.1%) 
(Figure 3). 
 
Univariable Poisson regression showed an increased risk of infection for administration of 
induction immunosuppression (IRR 1.48, 95%CI 1.07 to 2.05; P=0.019), higher MELD (IRR 
1.04, 95%CI 1.02 to 1.06; P<0.001) or Child-Pugh score (IRR 1.08, 95%CI 1.01 to 1.16; 
P=0.017) and vitamin D deficiency (IRR 1.52, 95%CI 1.08 to 2.15; P=0.018) (Table 2). No 
association with incident infections were found for age, sex, type of liver graft, BMI and self-
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reported mobility at time of transplantation. With regard to co-linearity between MELD and 
Child-Pugh score, only MELD score was added to the multivariable model (r=0.435, 
P<0.001). In multivariable analysis higher MELD score (IRR 1.03, 95%CI 1.01 to 1.05; 
P=0.003) correlated positively with risk of incident infections, whereas male sex was 
protective (IRR 0.67, 95%CI 0.45 to 0.98; P=0.040). No significant association with vitamin 
D levels was detected. 
 
Restricting Poisson regression to bacterial infections identified a positive correlation with 
increasing MELD (univariable IRR 1.05, 95%CI 1.03 to 1.07; P<0.001), Child-Pugh score 
(univariable IRR 1.17, 95%CI 1.06 to 1.28; P=0.001) as well as higher BMI (univariable IRR 
1.04, 95%CI 1.00 to 1.08; P=0.037) (Table 3). In a multivariable model male sex was 
associated with a lower risk of incident infections (IRR 0.52, 95%CI 0.30 to 0.91; P=0.021), 
but none of the additionally investigated variables, including vitamin D levels at time of 
transplantation, showed a significant association.  
 
Infections after 6 up to 30 months after liver transplantation 
A total of 158 infections affecting 68 individuals were recorded in this observation period, 
composed of 49 (31.0%) bacterial infections, 24 (15.2%) viral infections, 4 (2.5%) fungal 
infections and 81 (51.3%) infections without identification of the causative pathogen (Figure 
2). Bacterial infections most frequently were bacteremia (n=13, 26.5%) or affected the 
gastrointestinal tract (n=9, 18.4%), respiratory tract (n=8, 16.3%) or the skin and mucous 
membranes (n=8, 16.3%) (Figure 3). 
 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
In univariable analysis increasing age protected from infections (IRR per decade 0.83, 95%CI 
0.76 to 0.92; P<0.001), whereas vitamin D status, sex, type of liver graft, use of induction 
immunosuppression, BMI at 6 months post-transplant and self-reported mobility 6 months 
after transplantation did not show a significant association with incident infections. 
Multivariable analysis identified increased risk of incident infections in transplant recipient 
reporting major limitations in self reported mobility 6 months after transplantation (IRR 3.62, 
95%CI 1.01 to 12.90; P=0.047), solely. 
 
Focusing exclusively on bacterial infections vitamin D deficiency (IRR 2.29, 95%CI 1.06 to 
4.94; P=0.034) and male sex (IRR 3.34, 95%CI 1.41 to 7.92; P=0.006) increased risk of 
incident infections, but increasing age (IRR 0.84, 95%CI 0.70 to 1.00; P=0.049) was 
protective in univariable analysis (Table 3). Multivariable analysis only confirmed the 
positive correlation between male sex and incident infections (IRR 2.99, 95%CI 1.17 to 7.63; 
P=0.022). Notably, vitamin D status (IRR 1.09, 95%CI 0.45 to 2.66; P=0.844) lost its 
association after adjustment. 
Discussion 
In our study vitamin D status of liver allograft recipients was determined by uniform, 
centralized measurement utilizing prospectively collected samples gathered at the time of 
transplantation and 6 months post-transplant. Vitamin D deficiency was highly prevalent at 
both time points, transplantation and 6 months post-transplant. In longitudinal measurements, 
no significant change in 25-OHD levels was observed in liver graft recipients. Multivariable 
analyses did not confirm an association of vitamin D levels with incident infections or proven 
bacterial infections.  
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In chronic liver disease vitamin D deficiency is common [9]. Several reasons may contribute 
to persisting vitamin D deficiency after transplantation. Physicians might have prescribed an 
insufficient dose of vitamin D, which could be aggravated by an increased demand 
(compared to non-transplant patients) to reach normal vitamin D levels. Recent reports 
indicated that an initial loading dose is beneficial to replenish vitamin D levels [15]. Notably, 
none of our patients received a loading dose. Furthermore, transplant patients are instructed 
to avoid sun exposure, because of the increased risk of skin cancer due to 
immunosuppression, which results in omission of the most important vitamin D source. This 
hypothesis is also supported by the absence of a seasonal influence on 25-OHD 6 months 
post-transplant (Supplemental Table 1). In our opinion, malcompliance with prescribed 
supplementation therapy seems unlikely, but there was no assessment for compliance with 
supplementation therapy. Approaches to improve vitamin D supplementation therapy might 
benefit from a better knowledge of pharmacokinetics in transplant recipients [16, 17].  
 
Several studies support a link between vitamin D and antimicrobial effects; an impact on both 
innate and adaptive immunity is postulated. 1, 25-(OH)2 vitamin D can be produced by 
monocytes and macrophages via CYP27B1-hydroxylase using 25-OHD as necessary 
substrate. The produced 1, 25-(OH)2 vitamin D activates vitamin D receptor-directed genes 
such as cathelicidin and results in killing of the ingested pathogen [18, 19]. The active form 
of cathelicidin, LL-37, has been shown to be able to disrupt bacterial membranes and viral 
envelopes [20]. This mechanism seems not to be limited to monocytes and macrophages. 
Increasing evidence is present for barriers like skin [21], gut [22] and lung [23] being capable 
of using this pathway. This pathway might be hampered if an insufficient amount of 25-OHD 
is available. In cirrhotic patients a positive correlation between vitamin D deficiency and 
incident infections has been reported previously [9, 24]. In the present study, univariable 
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analyses showed an association of vitamin D deficiency and incident infections within the 
first 6 months (first observation period) and bacterial infections after 6 up to 30 months post-
transplant. However, multivariable analyses could not confirm these associations indicating 
that adjustment for confounders vanished the observation.  
 
Limitations of our study are the retrospective assessment of vitamin D supplementation. The 
strengths include serial 25-OHD measurement with uniform methods, the prospective study 
design and the availability of follow-up data up to 2.5 years post-transplant for almost all 
study participants. 
 
In conclusion, our study challenges the postulated role of vitamin D in infections after liver 
transplantation, as this association got lost after adjustment for multiple confounders. Despite 
supplementation therapy a relevant proportion of our patients were deficient or severely 
deficient, a finding in need of action. 
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Tables 
Table 1: Baseline characteristics 
Variable  
Age (median (IQR)) 54y (45-61) 
Sex (n, %) Male 87 (64.4%) 
Female 48 (35.6%) 
Ethnicity (n, %) Caucasian 132 (97.8%) 
Asian 2 (1.5%) 
African 1 (0.7%) 
Underlying disease (n ,%) Hepatitis C 30 (22.2%) 
Alcohol abuse 28 (20.7%) 
Hepatocellular carcinoma 22 (16.3%) 
Hepatitis B 15 (11.1%) 
Extrahepatic biliary atresia 5 (3.7%) 
Primary biliary cirrhosis 5 (3.7%) 
Extrahepatic biliary atresia 5 (3.7%) 
Cholangiocarcinoma 4 (3.0%) 
Primary sclerosing cholangitis 4 (3.0%) 
Other 17 (12.6%) 
MELD (median (IQR)) 20 (14-28) 
Child – Pugh stage* (n, %) A 44 (32.6%) 
B 42 (31.1%) 
C 29 (21.5%) 
Hepatorenal syndrome (n, %) Present, no RRT 18 (13.3%) 
Present, RRT 12 (8.8%) 
Absent, no RRT 98 (72.6%) 
Unknown 7 (5.2%) 
Type of donation (n, %) Deceased donor: DBD 126 (93.3%) 
Living donor:  
   related 6 (4.4%) 
   living unrelated 3 (2.2%) 
Type of transplant (n, %) Whole liver 121 (89.7%) 
Split liver 14 (10.4%) 
Induction therapy (n, %) Basiliximab 89 (65.9%)
##
 
Rituximab 1 (0.7%) 
None 45 (33.3%) 
Maintenance immunosuppression
#
 (n, %) Tac+MMF+steroids 17 (12.6%) 
Tac+MMF 24 (17.8%) 
Tac solely 17 (12.6%) 
CsA+MMF+steroids 8 (5.9%) 
CsA+MMF 20 (14.8%) 
CsA solely 7 (5.2%) 
MMF+steroids 4 (3.0%) 
Other regimen 38 (28.1%) 
Vitamin D supplementation (n, %) peri-transplant** 
cholecalciferol 24 (17.8%) 
1, 25-dihydroxycholecalciferol 2 (1.5%) 
None 108 (80.0%) 
 
6 months post-transplant*** 
cholecalciferol 55 (40.7%) 
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1, 25-dihydroxycholecalciferol 2 (1.5%) 
None 70 (51.9%) 
#
 at 6 months post-transplant 
##
 1 combined with glucocorticoids, 1 combined with rituximab 
* data for 20 participants missing  
** data for 1 participant missing 
*** data for 8 participants missing 
Abbreviations: CsA: cyclosporine A, DBD: donation after brain death, EC-MPA: enteric-coated 
mycophenolate, MELD: Model for End-Stage Liver Disease, MMF: mycophenolate mofetil, RRT: 
renal replacement therapy, Tac: tacrolimus 
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Table 2: Poisson regression analysis of risk for infections within the first 6 months post-transplant and after 6 up to 30 months post-
transplant 
 first 6 months post-transplant after 6 up to 30 months post-transplant 
 Univariable analysis Multivariable analysis Univariable analysis Multivariable analysis 
 Incidence rate ratio 
(95% CI) 
P Incidence rate ratio 
(95% CI) 
P Incidence rate ratio 
(95% CI) 
P Incidence rate ratio 
(95% CI) 
P 
Vitamin D status
#
 
   No deficiency 
   Deficiency 
 
Reference 
1.52 (1.08 to 2.15) 
 
 
0.018 
 
Reference 
1.19 (0.79 to 1.81) 
 
 
0.408 
 
Reference 
1.15 (0.81 to 1.64) 
 
 
0.430 
 
Reference 
1.19 (0.75 to 1.91) 
 
 
0.461 
Age 
   Per decade increase 
 
0.99 (0.90 to 1.09) 
 
0.875 
 
0.93 (0.79 to 1.08) 
 
0.323 
 
0.83 (0.76 to 0.92) 
 
<0.001 
 
0.93 (0.77 to 1.14) 
 
0.498 
Sex 
   Female 
   Male 
 
Reference 
0.79 (0.59 to 1.06) 
 
 
0.114 
 
 
0.67 (0.45 to 0.98) 
 
 
0.040 
 
Reference 
1.36 (0.95 to 1.96) 
 
 
0.094 
 
Reference 
1.19 (0.75 to 1.89) 
 
 
0.464 
MELD score* 
   Per point increase 
 
1.04 (1.02 to 1.06) 
 
<0.001 
 
1.03 (1.01 to 1.05) 
 
0.003 
    
Child-Pugh score* 
   Per point increase 
 
1.08 (1.01 to 1.16) 
 
0.017 
 
 
     
Type of graft 
   whole liver 
   split liver 
 
Reference 
1.02 (0.64 to 1.62) 
 
 
0.944 
 
 
1.31 (0.64 to 2.70) 
 
 
0.465 
 
Reference 
1.56 (0.97 to 2.50) 
 
 
0.065 
 
Reference 
1.15 (0.54 to 2.45) 
 
 
0.726 
Induction 
immunosuppression 
   None 
   Any 
 
Reference 
1.48 (1.07 to 2.05) 
 
 
0.019 
 
Reference 
1.53 (1.00 to 2.34) 
 
 
0.052 
 
Reference 
1.23 (0.86 to 1.76) 
 
 
0.262 
 
Reference 
0.89 (0.56 to 1.41) 
 
 
0.620 
BMI
#
 
   Per point increase 
 
1.02 (0.99 to 1.05) 
 
0.204 
 
1.01 (0.97 to 1.05) 
 
0.678 
 
0.98 (0.94 to 1.01)) 
 
0.218 
 
1.03 (0.97 to 1.08) 
 
0.353 
Mobility
#
 
   No problems 
   Some problems 
   Confined to bed 
 
Reference 
1.00 (0.71 to 1.42) 
2.04 (0.82 to 5.04) 
 
 
0.996 
0.125 
 
Reference 
0.84 (0.58 to 1.20) 
1.25 (0.48 to 3.25) 
 
 
0.333 
0.645 
 
Reference 
1.16 (0.77 to 1.76) 
3.16 (1.00 to 10.04)) 
 
 
0.474 
0.051 
 
Reference 
1.07 (0.68 to 1.69) 
3.62 (1.01 to 12.90) 
 
 
0.758 
0.047 
MELD: model of end stage liver disease 
* at time of transplantation 
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#
 assessment at time of transplantation and at 6 months post-transplant used for analysis of incident infections within first 6 months post-transplant and after 6 
up to 30 months post-transplant, respectively  
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Table 3: Poisson regression analysis of risk for bacterial infections within the first 6 months post-transplant and after 6 up to 30 months 
post-transplant 
 first 6 months post-transplant after 6 up to 30 months post-transplant 
 Univariable analysis Multivariable analysis Univariable analysis Multivariable analysis 
 Incidence rate  ratio 
(95% CI) 
P Incidence rate 
ratio (95% CI) 
P Incidence rate 
ratio (95% CI) 
P Incidence rate ratio 
(95% CI) 
P 
Vitamin D status
#
 
   No deficiency 
   Deficiency 
 
Reference 
1.49 (0.92 to 2.41) 
 
 
0.106 
 
Reference 
0.96 (0.54 to 
1.70) 
 
 
0.879 
 
Reference 
2.29 (1.06 to 
4.94) 
 
 
0.034 
 
Reference 
1.09 (0.45 to 2.66) 
 
 
0.844 
Age  
   Per decade increase 
 
1.00 (0.88 to 1.15) 
 
0.973 
 
0.99 (0.78 to 
1.25) 
 
0.901 
 
0.84 (0.70 to 
1.00) 
 
0.049 
 
0.79 (0.56 to 1.11) 
 
0.170 
Sex 
   Female 
   Male 
 
Reference 
0.80 (0.53 to 1.20) 
 
 
0.278 
 
 
0.52 (0.30 to 
0.91) 
 
 
0.021 
 
Reference 
3.34 (1.41 to 
7.92) 
 
 
0.006 
 
Reference 
2.99 (1.17 to 7.63) 
 
 
0.022 
MELD score* 
   Per point increase 
 
1.05 (1.03 to 1.07) 
 
<0.001 
 
1.02 (0.99 to 
1.06) 
 
0.131 
    
Child-Pugh score* 
   Per point increase 
 
1.17 (1.06 to 1.28) 
 
0.001 
      
Type of graft 
   whole liver 
   split liver 
 
Reference 
1.32 (0.74 to 2.37) 
 
 
0.349 
 
Reference 
1.20 (0.41 to 
3.52) 
 
 
0.741 
 
Reference 
0.47 (0.11 to 
1.95) 
 
 
0.299 
 
 
 
 
 
Induction 
immunosuppression 
   None 
   Any 
 
Reference 
1.46 (0.93 to 2.30) 
 
 
0.103 
 
Reference 
1.48 (0.78 to 
2.81) 
 
 
0.227 
 
Reference 
1.17 (0.61 to 
2.24) 
 
 
0.641 
 
 
 
BMI
#
 
   Per point increase 
 
1.04 (1.00 to 1.08) 
 
0.037 
 
1.03 (0.96 to 
1.10) 
 
0.403 
 
0.96 (0.89 to 
1.03) 
 
0.228 
 
0.95 (0.86 to 1.04) 
 
0.267 
Mobility
#
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   No problems 
   Some problems 
   Confined to bed 
Reference 
0.91 (0.55 to 1.51) 
0.84 (0.12 to 6.12) 
 
0.711 
0.862 
Reference 
0.73 (0.43 to 
1.23) 
0.49 (0.06 to 
3.77) 
 
0.239 
0.493 
Reference 
1.54 (0.73 to 
3.23) 
4.05 (0.54 to 
30.27) 
 
0.256 
0.173 
Reference 
1.63 (0.75 to 3.50) 
3.70 (0.40 to 
34.04) 
 
0.216 
0.248 
MELD: model of end stage liver disease 
* at time of transplantation 
#
 assessment at time of transplantation and at 6 months post-transplant used for analysis of incident infections within first 6 months post-transplant and after 6 
up to 30 months post-transplant, respectively
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
Figure legends 
Figure 1: Distribution of 25-OH vitamin D values of liver transplant recipients peri-transplant 
and 6 months post-transplant 
 
Figure 2: Infections occurring in the first 6 months after transplantion and more than 6 up to 
30 months post-transplant 
 
Figure 3: Site of infection in bacterial infections after liver transplantation 
 
Appendices 
The members of the Swiss Transplant Cohort Study are: Patrizia Amico, John-David Aubert, 
Vanessa Banz, Guido Beldi, Christian Benden, Christoph Berger, Isabelle Binet, Pierre-Yves 
Bochud, Elsa Boëly, Heiner Bucher, Thierry Carell, Emmanuelle Catana, Yves Chalandon, 
Sabina de Geest, Olivier de Rougemont, Michael Dickenmann, Michel Duchosal, Laure 
Elkrief, Thomas Fehr, Sylvie Ferrari-Lacraz, Christian Garzoni, Paola Gasche Soccal, 
Christophe Gaudet, Emiliano Giostra, Déla Golshayan, Karine Hadaya, Jörg Halter, Dominik 
Heim, Christoph Hess, Sven Hillinger, Hans H. Hirsch, Günther Hofbauer, Uyen Huynh-Do, 
Franz Immer, Richard Klaghofer, Michael Koller (Head of the data center), Bettina Laesser, 
Roger Lehmann, Christian Lovis, Pietro Majno; Oriol Manuel, Hans-Peter Marti, Pierre Yves 
Martin, Pascal Meylan, (Head, Biological samples management group), Paul Mohacsi, 
Philippe Morel, Ulrike Mueller, Nicolas J Mueller (Chairman Scientific Committee), Helen 
Mueller-McKenna (Head of local data management), Antonia Müller, Thomas Müller, Beat 
Müllhaupt, Manuel Pascual (Executive office), Jakob Passweg, Klara Posfay-Barbe, Juliane 
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Rick, Eddy Roosnek, Anne Rosselet, Silvia Rothlin, Frank Ruschitzka, Urs Schanz, Stefan 
Schaub, Aurelia Schnyder, Christian Seiler, Jan Sprachta; Susanne Stampf, Jürg Steiger 
(Head, Executive Office), Guido Stirnimann, Christian Toso, Christian Van Delden 
(Executive office), Jean-Pierre Venetz, Jean Villard, Madeleine Wick (STCS coordinator), 
Markus Wilhelm, Patrick Yerly.  
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